Destroying c-Jun Messenger: New Insights into Biological Mechanisms of DNAzyme Function
Destroying c-Jun Messenger: New Insights into Biological Mechanisms of DNAzyme Function |
|
https://doi.org/10.18632/oncotarget.549
Levon M. Khachigian,
Hong Cai,
Fergal J. Moloney,
Christopher R. Parish,
Beng H. Chong,
Roland Stocker,
Ross St.C. Barnetson,
and Gary M. Halliday
|
| 594-595 |
Cyclotherapy: opening a therapeutic window in cancer treatment
Cyclotherapy: opening a therapeutic window in cancer treatment |
|
https://doi.org/10.18632/oncotarget.524
Ingeborg M.M. van Leeuwen
|
| 596-600 |
Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells
Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells |
|
https://doi.org/10.18632/oncotarget.548
Mikhail V. Blagosklonny
|
| 601-607 |
Targeting of Rac GTPases blocks the spread of intact human breast cancer
Targeting of Rac GTPases blocks the spread of intact human breast cancer |
|
https://doi.org/10.18632/oncotarget.520
Elad Katz,
Andrew H. Sims,
Duncan Sproul,
Helen Caldwell,
J. Michael Dixon,
Richard R. Meehan,
and David J. Harrison
|
| 608-619 |
Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival
Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival |
|
https://doi.org/10.18632/oncotarget.521
J Scott Nystrom,
John C. Hornberger,
Gauri R. Varadhachary,
Richard J. Hornberger,
Hialy R. Gutierrez,
W. David Henner,
Shawn H. Becker,
Mahul B. Amin,
and Michael G. Walker
|
| 620-628 |
Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton
Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton |
|
https://doi.org/10.18632/oncotarget.525
Efrat Mashiach Farkash,
Roni Rak,
Galit Elad-Sfadia,
Roni Haklai,
Shmuel Carmeli,
Yoel Kloog,
and Haim Wolfson
|
| 629-639 |
A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy
A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy |
|
https://doi.org/10.18632/oncotarget.543
Dipankar Pramanik,
Nathaniel R Campbell,
Samarjit Das,
Sonal Gupta,
Venugopal Chenna,
Savita Bisht,
Polina Sysa-shah,
Djahida Bedja,
Collins Karikari,
Charles Steenbergen,
Kathleen L. Gabrielson,
Amarnath Maitra,
and Anirban Maitra
|
| 640-650 |
Sox9 is required for prostate development and prostate cancer initiation
Sox9 is required for prostate development and prostate cancer initiation |
|
https://doi.org/10.18632/oncotarget.531
Zhenhua Huang,
Paula J. Hurley,
Brian W. Simons,
Luigi Marchionni,
David M. Berman,
Ashley E. Ross,
and Edward M. Schaeffer
|
| 651-663 |
